<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27940">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742987</url>
  </required_header>
  <id_info>
    <org_study_id>CLOTILDIA</org_study_id>
    <nct_id>NCT02742987</nct_id>
  </id_info>
  <brief_title>Clopidogrel Versus Ticagrelor in Type-2 Diabetes</brief_title>
  <official_title>CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study
      evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function
      and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with
      percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation of the brachial artery</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-occlusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with flow-mediated dilation of the brachial artery &lt;7%</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium-independent dilation of the brachial artery</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent dilation of the brachial artery, as assessed with vascular ultrasound, from baseline to post-administration of 0.5 mg sublingual nitroglycerin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Platelet reactivity assessed with the VerifyNow P2Y12 Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with platelet reactivity &gt;256 P2Y12 reaction units</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ticagrelor group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90 mg twice daily + standard medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel 150 mg once daily + standard medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90 mg twice daily</description>
    <arm_group_label>Ticagrelor group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 150 mg once daily</description>
    <arm_group_label>Clopidogrel group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard medical therapy</intervention_name>
    <description>Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
    <arm_group_label>Ticagrelor group</arm_group_label>
    <arm_group_label>Clopidogrel group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  stable coronary disease

          -  coronary revascularization with PCI at least 1 month prior to recruitment

        Exclusion Criteria:

          -  acute coronary syndrome

          -  platelet count &lt;70x109/l

          -  active bleeding or bleeding diathesis

          -  history of intracranial bleeding

          -  gastrointestinal bleeding &lt;6 months

          -  cerebrovascular accident &lt;3 months

          -  history of malignancy

          -  concomitant need for oral anticoagulant therapy

          -  severe liver disease or chronic renal failure (glomerular filtration rate &lt;30 ml/min
             /1.73m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 14, 2016</lastchanged_date>
  <firstreceived_date>March 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Germano Di Sciascio</investigator_full_name>
    <investigator_title>Prof. Germano Di Sciascio</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
